

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



聯康生物科技集團有限公司*

Uni-Bio Science Group Limited

(incorporated in the Cayman Islands with limited liability)

(stock code: 690)

ANNOUNCEMENT

This announcement is made in accordance to Rule 13.09 of the Listing Rules.

The Board of directors wishes to update the shareholders on the development and progress of the application for resumption of trading of the Company's shares in the Stock Exchange of Hong Kong Limited (the "**Exchange**").

References are also made to the announcements (the "**Announcements**") of the Company dated 6 February 2012, 10 October 2012 and 4 December 2012.

In November 2012, the Company engaged BDO Financial Services Limited ("**BDO**") to perform an Internal Control Review of the Company and its Subsidiaries (the "**Group**"). The report is expected to be finished by March 2013 and will be submitted to the Exchange. The Company will then discuss the resumption of trade with the Exchange in due course.

The Company is currently engaged in discussion with the Stock Exchange over the question as to the resumption of trading of shares in the Company. Further announcement will be made by the Company in the event of a material development of the resumption process

By order of the Board
Uni-Bio Science Group Limited
TONG Kit Shing
Chairman

Hong Kong, 27 February 2013

* *For identification purpose only*

As at the date of this announcement, the executive directors of the Company are Mr. TONG Kit Shing (Chairman), Mr. LIU Guoyao and Mr. LEUNG Ka Chun; the independent non-executive directors of the Company are Mr. TSAO Hoi Ho, Terry, Mr. Mr. LOU Iok Kuong, Mr. NG Pak Kin, Danny and Mr. LEUNG Wai Chung, Vincent.